1. Home
  2. News
  3. Veritas In Silico Inc.
  4. Joint Patent Application Filed for lncRNA-Targeting Drugs
More Veritas In Silico Inc. news
Veritas In Silico Inc.TSE: 130A

Joint Patent Application Filed for lncRNA-Targeting Drugs

Aug 2, 2026 at 11:00 PM EDT · Issued by Veritas In Silico Inc. via TDnet

Filed with TSE · Aug 2, 2026 at 11:00 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/joint-patent-application-filed-for-lncrna-targeting-drugs

Veritas In Silico Inc. on 6ix

In the deck

  • Veritas In Silico — Q2 2026 Earnings Presentation34 slidesAug 5, 2026

Earlier from Veritas In Silico

  • Personnel Changes in Executive OfficerJul 13
  • TABLE-Veritas In Silico -2025 parent resultsFeb 11
  • TABLE-Veritas In Silico - 9-MTH parent resultsNov 11, 2025
  • TABLE-Veritas In Silico -2025 parent forecastOct 14, 2025

Later from Veritas In Silico

  • Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]Aug 5
  • Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.Oct 19
  • Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party AllotmentOct 29
  • Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted CompoundsNov 2
  • Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment OptioNov 2
All Veritas In Silico news releases↗

Follow Veritas In Silico into a list and get an email when it puts out news.

Follow Veritas In Silico
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer